InsidersTradesSigma
Total declarations
Company
▲ Purchases (10 ops.)
▼ Sales (0 ops.)
Discover the detailed record of transactions filed by Kunin Audrey, Directeur Produit. Insider active across 1 companies, notably NovaBay Pharmaceuticals, Inc.. Aggregated, 10 filings have been recorded. Total volume traded: €362k. The latest transaction was filed on 3 December 2021 (Acquisition). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations10 total
€41,582101,650 shares@ €0.40910.080% mcap23.0% of flow
Common Stock
SEC:0001437749-21-028027·
Ideal exit: 30 Aug 2022 (T+270)
€41,582101,650 shares@ €0.40910.080% mcap11.5% of flow
Common Stock
SEC:0001437749-21-028027:0·
Ideal exit: 30 Aug 2022 (T+270)
€110,329262,369 shares@ €0.42050.21% mcap61.0% of flow
Common Stock
SEC:0001437749-21-027934·
Ideal exit: 29 Aug 2022 (T+270)
€110,329262,369 shares@ €0.42050.21% mcap30.5% of flow
Common Stock
SEC:0001437749-21-027934:0·
Ideal exit: 29 Aug 2022 (T+270)
€6,42114,848 shares@ €0.43250.012% mcap3.6% of flow
Common Stock
SEC:0001437749-21-027852·
Ideal exit: 28 Aug 2022 (T+270)
€6,42114,848 shares@ €0.43250.012% mcap1.8% of flow
Common Stock
SEC:0001437749-21-027852:0·
Ideal exit: 28 Aug 2022 (T+270)
€12,21930,000 shares@ €0.40730.024% mcap6.8% of flow
Common Stock
SEC:0001437749-21-027706·
Ideal exit: 27 Aug 2022 (T+270)
€12,21930,000 shares@ €0.40730.024% mcap3.4% of flow
Common Stock
SEC:0001437749-21-027706:0·
Ideal exit: 27 Aug 2022 (T+270)
€10,19925,000 shares@ €0.4080.020% mcap5.6% of flow
Common Stock
SEC:0001437749-21-027397·
Ideal exit: 19 Aug 2022 (T+270)
€10,19925,000 shares@ €0.4080.020% mcap2.8% of flow
Common Stock
SEC:0001437749-21-027397:0·
Ideal exit: 19 Aug 2022 (T+270)
10 of 10 declarations
About Kunin Audrey
Audrey Kunin is the Chief Product Officer at NovaBay Pharmaceuticals, Inc. She oversees the development of new products and innovation within the company. Her expertise in research and development is essential for the success of the company's initiatives. Audrey is committed to improving patient outcomes through innovative solutions.
